Dengue Vaccine: Considerations before Rollout in Colombia

Christian Julian Villabona-Arenas; Raquel Elvira Ocazionez Jimenez; Cinthy Lorena Jimenez Silva

doi:10.1371/journal.pntd.0004653

Dengue Vaccine: Considerations before Rollout in Colombia

PLoS Negl Trop Dis. 2016 Jun 9;10(6):e0004653. doi: 10.1371/journal.pntd.0004653. eCollection 2016 Jun.

Authors

Christian Julian Villabona-Arenas^{1

2}, Raquel Elvira Ocazionez Jimenez³, Cinthy Lorena Jimenez Silva³

Affiliations

¹ UMI233, Institut de Recherche pour le Développement (IRD), Université de Montpellier, Montpellier, France.
² Laboratoire d'Informatique, de Robotique et de Microélectronique de Montpellier (LIRMM), Institut de Biologie Computationnelle (IBC), Université de Montpellier, Montpellier, France.
³ Laboratorio de Arbovirus, Centro de Investigaciones en Enfermedades Tropicales (CINTROP), Universidad Industrial de Santander, Santander, Colombia.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Child
Child, Preschool
Colombia / epidemiology
Dengue / epidemiology*
Dengue / prevention & control*
Dengue Vaccines / adverse effects*
Dengue Vaccines / immunology*
Dengue Virus / classification*
Health Services Accessibility
Humans
Infant
Serogroup

Substances

Dengue Vaccines

Grants and funding

This work was supported by grants from Colciencias (1102-04-16376 and 1102-04-13042), the Gobernación de Santander (2007-068000-0070), and the Sistema General de Regalías, Fondo de Ciencia, Tecnología e Innovación co-financed by Sanofi Pasteur (BPIN # 2013-0001-00011-P2). CJVA was supported by a fellowship from the Labex EpiGenMed via the National Research Agency, Programme for Future Investment ANR-10-LABX-12-01 and the University of Montpellier. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript